GRAND RAPIDS, Mich. & EMERYVILLE, Calif—May 3, 2007—The Van Andel Research Institute an independent medical research facility known for its research into the genetic and molecular origins of cancer and other diseases and Emiliem, Inc. a private biotechnology company focused on the discovery and development of molecularly-targeted oncology drugs and their companion biomarkers, announce the signing of an Agreement where Van Andel and Emiliem will work together to translate Emiliem's discoveries into therapies to conquer cancer and enhance lives. Financial details of the multi-year agreement were not disclosed.
